







VIPIN KUMAR, POONAM TAYA,*NEETU 
Institute of Pharmaceutical Sciences, Kurukshetra University, Kurukshetra 136119, India. 
Email: pttayapoonam08@gmail.com 
Received: 03 May 2014 Revised and Accepted: 14 June 2014 
ABSTRACT  
Objective: The present study is wrought to design the 3D QSAR models on pyrrolopyrimidines as p-glycoprotein inhibitors for the treatment of a 
wide variety of diseases. 
Methods: A dataset comprising of 33 pyrrolopyrimidine derivatives have been divided into training set and test set. A three dimensional 
pharmacophore hypotheses were built from training set (24 compounds) using hydrogen bond acceptor, hydrophobic and aromatic features.  
Results: The proposed model possesses high value of regression coefficient (0.9334) and was validated by using test set predictions. The squared 
predictive correlation coefficient of 0.985 was observed between experimental and predicted activity values of test set molecules. 
Conclusion: The nature of fitness and the distance between pharmacophoric features explain the inhibitory activity of pyrollopyrimidines. The 
proposed pharmacophoric models possess as potential for the design of novel p-glycoprotein inhibitors.  
Keywords- P-glycoprotein, MDR, 3D-QSAR, Pharmacophore hypothesis, Regression coefficient, Squared predictive correlation coefficient. 
 
INTRODUCTION 
The development of pharmacological agents able to counteract the 
mechanisms of drug resistance in oncology has remained a major 
goal for the past 10 years and this is the most ascertained cause of 
failure in cancer therapy.(1,2)
The main role of P-gp is likely to protect the susceptible organs from 
toxic compounds and preventing them to enter the cytosol. 
 Multidrug resistance (MDR) is the term 
that is used to describe the broad pattern of cross resistance appears 
after prolonged exposure of cells to a single drug, and it is 
characterized by resistance to a series of structurally unrelated 
compounds with different subcellular targets.(3,4) High level of P-gp 
results in a lower intracellular accumulation of drug and an increase 
in efflux and MDR is caused by the overexpression of efflux 
transporters such as ABCB1 and ABCG2, located in the plasma 
membrane of cancer cells, actively extruding a vast number of 
structurally unrelated compounds, including many commonly used 
anticancer drugs. (5,6)  
(7) P-
glycoprotein (P-gp) is a 170-kDa membrane protein and member of 
the ATP binding cassette (ABC) super family of secretory transport 
proteins(8).
The structural core of ABC transporters consists of two membrane 
domains composed of six trans-membrane helical segments each 
and two nucleotide binding domains located at the cytoplasmic 
surface of the membrane.
 Human ATP binding cassette (ABC) transporters belong 
to a family of 49 genes classified into seven subfamilies: ABC-A, ABC-
B, ABC-C, ABC-D, ABC-E, ABC-F and ABC-G among theseABC-B1; 
better known as P-glycoprotein (P-gp) (9).  
(10). P-gp confers resistance to drugs by 
preventing their accumulation within the cell. P-gp’s efflux 
capabilities appear to reflect its ability to bind substrates within the 
inner leaflet of the plasma membrane. Subsequently, and in a 
potentially ATP-dependent manner, substrates are expelled from the 
cell.(11) The typical multidrug resistance in tumor cells is associated 
with a decreased cellular drug accumulation achieved through ATP-
dependent transport of the drugs out of cells by P-glycoprotein.(12) 
Researchers have demonstrated that drug does not cross the 
endothelial lining of the in vivo BBB due to the presence of P-gp 
localized on the blood-facing surface. (13-15) P-gp activity inhibition is 
a way of reversing MDR, and it has been extensively studied for 
more than 2 decades and some second-generation P-gp modulators 
have been developed, including (+)-verapamil (dexverapamil) and 
biricodar and these agents are more potent and less toxic than the 
first generation modulators.
An obvious starting point to circumvent MDR in P-gp expressing 
cells is to design the novel chemotherapeutic agents that are not 
recognized/transported by the pump
(16) 
(17) A series of substituted 
pyrrolopyrimidines inhibit the function of p-glycoprotein without 
modulating multidrug resistance-related protein (MRP).These 
compounds have their toxicity towards drug sensitive tumor cells 
and have their ability to antagonize the p-glycoprotein mediated 
resistant cells and MRP-1 mediated resistant cells.
The concept of pharmacophore was first introduced in 1909 by 
Ehrlich, who defined the pharmacophore as ‘a molecular framework 
that carries (phoros) the essential features responsible for a drug’s 
(pharmacon) biological activity. 
(18) 
(19) A pharmacophore refers to the 
three dimensional (3D) arrangement of atoms or functional groups 
in a molecule necessary for the compound to bind to a specific 
enzyme or receptor (20). The computational models can be generated 
and validated utilizing either the 3D structure of the target or a set 
of active analogues specific to the target or by combining 
information from structure of the drug target and a set of active 
analogues specific to the target. (21) 3D database pharmacophore 
searching attempts to identify molecules in a database on the basis 
of their possessing a particular pharmacophore in their structure, 
expressed necessarily in three dimensions (22). Pharmacophore 
modeling and 3D database searching are integral components of 
lead discovery and lead optimization, and the continuing need for 
improved pharmacophore based tools has driven the development 
of PHASE (23) The discovery of an innovative new chemical entity 
requires three key steps: the discovery of relevant biological targets, 
the generation of “lead” compounds, and the optimization of these 
leads.(24) Mukesh C. Sharma used the the molecular modeling 
software package VLife Molecular Design Suite version 3.5_3D for 
the study of substituted benzimidazole derivatives as 
dipeptidylpeptidase IV inhibitors.(25) Simone Brogi wield a Software 
Phase to derive a 3D-QSAR model based, as alignment rule, on a 
pharmacophore built on three compounds highly active against 
MCF-7 cell line(26). Vivek K. Vyas et al established the Pharmacophore 
models of PKB _ inhibitors using the DISCOtech.(27) Maria L. Lopez-
Rodriguez optimized a pharmacophore model for 5-HT7R 
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antagonism, with the incorporation of recently reported ligands and 
using an efficient procedure with the CATALYST program.(28)
In the present investigation, 33 pyrrolopyrimidine derivatives 
having p-glycoprotein inhibitory activity were considered 
 
Pharmacophore models from the ligand based approach are very 
useful for analyzing receptor ligand interactions. The generated 
pharmacophore model can be useful for rational design and 
identifying novel active compounds through a database search. The 
purpose of pharmacophore is to perform in silico screening searches 
in a 3 dimensional database of a virtual or real compound library to 
find diverse structures with desired binding activity and selectivity. 
The purpose of present work is to develop a rapid and robust, 
chemical feature based 3-dimensional pharmacophore model to 
predict the p-glycoprotein inhibitory activity. In addition, we aim to 
gain more information that could be used in further development 
and optimization of such p-glycoprotein inhibitors. To reach our 
objective, we used a series of substituted pyrrolopyrimidines that 
have their toxicity towards drug sensitive tumor cells and 
antagonize p-glycoprotein. 
MATERIALS AND METHODS 
Dataset 
(18).
These compounds were evaluated in drug accumulation assays using 
Pg-p expressing cell line. The p-glycoprotein
 Data 
set of compounds considered were divided randomly into training 
set and test set by considering the 75% of the total molecules in the 
training set and 25% in the test set.  






















 i.e., concentration in μM required for 50% 
inhibition of activity Twenty four molecules forming the training set 
were used to generate pharmacophore models and prediction of the 
activity of test set (08 analogues) molecules was used as a method to 
validate the proposed models.. The basic structure for these 
analogues is shown in Fig.1 and various substituents are enlisted in 
Table 1.  
 
Fig. 1: Basic structure of Pyrrolopyrimidines
 
Table 1: Experimental inhibitory activity of compounds towards P-glycoprotein 
Compound 
no 
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CN 2-CH3 17.99 -Ph 2.28 
  
Pharmacophore modeling 
The pharmacophore modeling studies were performed using 
‘PHASE’: a module of Schrödinger's software program ’MAESTRO. (29) 
The continuing need for improved pharmacophore based tools has 
driven the development of ‘PHASE’. To reach our research objectives 
we used ‘PHASE’: a module of Schrödinger's software program 
‘MAESTRO’
Preparation of ligands 
(30) 
The first step for pharmacophore mapping was ligand preparation. 
The chemical structures of all the compounds were drawn in 
maestro and geometrically refined using the option ‘clean 
structures’ and ‘generate confermers’, produces a single, low-energy, 
3D structure with correct chiralities for each successfully proposed 
input structure. While performing this step, chiralities were 
determined from 3D structure and original states of ionization were 
retained. Tautomers were generated using MacroModel method 
discarding current conformers. The conformations were generated 
by the Monte Carlo (MCMM) method as implemented in MacroModel 
version 9.6 using a maximum of 2,000 steps with a distance-
dependent dielectric solvent model and an OPLS-2005 force field. All 
the conformers were subsequently minimized using truncated 
Newton conjugate gradient (TNCG) minimization up to 500 
iterations. For each molecule, a set of conformers with a maximum 
energy difference of 30 kcal/mol relative to the global energy 
minimum conformer was retained.  
Pharmacophore modeling  
A common pharmacophore hypothesis is a spatial arrangement of 
chemical features common to two or more active ligands,which is 
proposed to explain the key interactions involved in ligand binding. 
Phase uses chemical features that was not an atomistic description 
of the compounds but a description of chemical 
properties(e.g.,hydrogen bond donor or acceptor, etc.) to build up 
the pharmacophores. A pharmacophore model or hypothesis is a 
collection of chemical features placed in 3D space that represent the 
most important characterstics of a ligand to bind to its receptor or 
have a certain biological affinity. Once a pharmacophore model is 
established, a beneficial use of it is 3D database searching to retrieve 
novel compounds that would match the pharmacophore. Common 
features hypothesis generated by phase are designed specifically for 
finding chemical features shared by a set of selective p-gp inhibitors 
and for providing the compounds relative alignment with a 
particular common features hypothesis. At the beginning of the 
hypothesis generation every conformer of each molecule was 
examined for the presence of chemical functions which will be 
selected and used to build the parmacophore hypothesis. Each 
hypothesis is scored according to how well the active ligands 
superimpose when they are aligned on the features associated with 
that hypothesis. A set of seven hypothesis were generated with 28 
compounds. 
Only the active ligands are normally considered when developing 
common pharmacophore hypothesis.Inactives can be used to 
eliminate hypothesis that do not provide a good explanation of 
activity on the basis of pharmacophore alone. The inactives scores 
may be used to assigned adjusted score that reflect the degree to 
which the models distinguish actives from inactives. For generating 
a phamacophore hypothesis a set of pharmacophore features were 
created using ’create sites’ option.The chemical feature types are 
hydrogen-bond acceptor (A), hydrogen bond donor (D), 
hydrophobic group (H) and aromatic ring (R),negative (N).In the 
present study three features donor (D),hydrophobic group(H), 
aromatic ring(R) could effectively map all critical chemical features 
of all the ligands. The minimum and maximum sites for all the 
features were kept 4 by “maximum and minimum columns’’ in 
‘features frequency’ table. pharmacophore from all conformations of 
the active ligands were examined and those pharmacophore that 
contained identical set of features with very similar spatial 
arrangement were grouped together. These features were selected 
and used to build a series of hypothesis with the find common 
pharmacophore option in Phase. 
Scoring Hypothesis 
In the next step, common pharmacophores were examined and a 
scoring procedure were applied to identify the pharmacophore that 
yields the best alignment of the active ligands.This pharmacophore 
provided a hypothesis to explain how the active ligands bind to 
receptor. The quality of alignment were measured by survival 
score.(31)
Build QSAR model  
 This scoring procedure provides a ranking of the different 
hypothesis to make rational choices about which hypothesis are the 
most appropriate for the model. 
All the ligands were separated into training and test.In this partial 
least square (PLS) regression was applied to dataset to obtain a 3D 
QSAR model. From this it was encoded that ligand atoms or features 
occupied the various cubes. We can set the size of the cubes by 
changing the value in the Grid spacing text box. The regression is 
done by constructing a series of models with an increasing number 
of PLS factors. In present case, the pharmacophore based model 
were generated by keeping 1Å grid spacing and 3 as maximum 
number of PLS factors.  
Validation  
Validation is a crucial aspect of pharmacophore design, particularly 
when the model is built for the purpose of predicting activities of 
compounds in external test series. In the present case the good 
predicted power of this model is indicated by the high correlation 
coefficient between experimental and predicted activity values. 
RESULTS AND DISCUSSIONS 
P-glycoprotein (P-gp) a member of the ABC transporter superfamily 
confers resistance to drugs by preventing their accumulation within 
the cell or by pumping chemotherapeutic drugs from the cytoplasm. 
(32,33) When the mechanisms of multidrug resistance have been 
identified, the hope of identifying molecules able to reverse 
simultaneously the resistance to a number of unrelated drugs has 
stimulated research in this field.(34) 
The ultimate goal of quantitative structure-activity relationship 
(QSAR) studies is the design of new, more-active, and selective 
compounds. 
Application of computational 
methodologies in the drug discovery process is well established. In 
virtual screening, computational models are used to predict the 
biological activity of compounds.  
(32) The interest in the idea of pharmacophores has been 
grown tremendously due to the availability of computer graphics, a 
number of computational methods to determine the 
pharmacophoric geometry and various softwares for 3D database 
mining using the concept of a pharmacophore pattern match.(35) In 
this current study, we have used the molecular structures of 
substituted pyrrolopyrimidines. These ligands were used to 
generate a common feature 3D pharamacophore. The 
pharmacophore alignment consisted of features two acceptors, one 
hydrophobic group (H) and one aromatic ring (R) which indicate 
that they are the important features for interaction. The purpose of 
pharmacophore modeling is to perform in silico screening searches 
in a 3 dimensional database of a virtual or real compound library to 
find diverse structures with desired binding activity and selectivity 
(36). In the present study, a series of pyrrolopyrimidines were 
considered for molecular modeling studies. The studies were aimed 
at developing a ligand based pharmacophore model relating the P-
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glycoprotein inhibitory activity of pyrrolopyrimidines to gain a 
greater understanding of the P-gp– ligand interactions. Twenty four 
molecules forming the training set were used to develop the 
pharmacophore models. The pharmacophoric features selected for 
creating sites were hydrogen bond acceptors, hydrophobic region (H) 
and aromatic ring (R). The three and five featured pharmacophore 
hypotheses were rejected due to low value of survival score, as they 
were unable to define the complete binding space of the selected 
molecules. Four featured pharmacophore hypotheses were selected and 
subjected to stringent scoring function analysis.  
The results of four featured pharmacophore hypotheses, labeled 
AAHR1, AAHR2, AAHR3, AAHR4, AAHR5 and AAHR6 are presented 
in Table. 2. The hypothesis AAHR4 is the best hypothesis in this 
study, characterized by good survival score, highest F value and the 
best regression coefficient (0.9334). The AAHR4 pharmacophore 
hypothesis is presented in Fig.2. The features represented by this 
hypothesis are two hydrogen bond acceptors, one hydrophobic 
group (H) and one aromatic ring (R). The angles and distances 
between different sites of AAHR.6 are given in Table.3 and table.4 
respectively.
 
Table 2: Parameters of different three featured hypothesis 
Hypothesis no Hypothesis  Survival score   R  F 2 
 1.  AAHR.1 3.639  0.864  44.8 
 2.  AAHR2 3.639  0.791  26.5 
 3.  AAHR3 3.436  0.920  80.7 
 4.  AAHR4  3.436  0.933  98.1 
 5.  AAHR5  2.49  0.829  34.1 
 6.  AAHR6  2.49  0.688  15.5 
 
Table 3: Distances between different sites 
Site1 Site2 Distance 
A1 A2 3.882 
A1 H6 5.233 
A1 R10 3.777 
A2 H6 5.391 
A2 R10 2.545 
H6 R10 2.851 
 
Table 4: Angle between different sites 
Site1 Site2 Site3 Angle 
A2 A1 H6 70.7 
A2 A1 R10 38.8 
H6 A1 R10 32.0 
A1 A2 H6 66.4 
A1 A2 R10 68.4 
H6 A2 R10 2.7 
A1 H6 A2 42.8 
A1 H6 R10 2.7 
A1 H6 A2 42.8 
A1 H6 R10 44.6 
A2 H6 R10 2.5 
A1 R10 A2 72.8 
A1 R10 H6 103.4 
A2 R10 H6 174.8 
  
 
Fig. 2: PHASE generated pharmacophore model AAHR4 
illustrates hydrogen bond acceptor (A1, A2; pink), aromatic 
ring (R10; orange) and hydrophobic ring (H6; green). 
 
For each ligand, one aligned conformer based on the lowest RMSE of 
feature atom coordinates from those of the corresponding reference 
feature was superimposed on AAHR4 hypothesis.  
Then fitness scores for all ligands were observed on the best scored 
pharmacophore model. The greater the fitness score, the greater the 
activity prediction of the compound.  
The fit function does not only check if the feature is mapped or not, 
it also contains a distance term, which measures the distance that 
separates the feature on the molecule from the centroid of the 
hypothesis feature. Fig.3 shows the alignment of compound no 17 
(antagonism at IC50 
Besides this survival score analysis, the validity and predictive 
character of AAHR4 were further assessed by using test set 
molecules. A test set having eight molecules was analyzed. All the 
test set molecules were built and minimized as well as used in 
conformational analysis like all training set molecules. 
= 10.52) of the training set having max fitness 
score. 
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Fig. 3: Best pharmacophore model AAHR.6 aligned with the 
compound having max fitness score. Pharmacophore features 
are color coded: hydrogen bond acceptor (A1, A2; pink), 
aromatic ring (R10; orange) and hydrophobic ring (H6; green). 
Then the activities of test set molecules were predicted using AAHR4 
and compared with the actual activity. Actual and predicted activity 
values of test set molecules are given in Table 5. The predicted P-gp 
inhibitory activity exhibited a squared predictive correlation 
coefficient of 0.9835 with reported P-gp inhibitory activity using 
model AAHR4 (Fig.4). For a reliable model, the squared predictive 
correlation coefficient should be >0.60 
The result of this study reveals that model AAHR4 can be used for 
the prediction of P-gp inhibitory activity.  
(37,25)  
Good and consistent external predictivity was observed for AAHR4 
as compared to the others. AAHR4 showed a good r2
 
 value, i.e. 
0.9308 and squared predictive correlation coefficient of 0.9835 was 
also observed between experimental and predicted activity values of 
test set molecules. 
Table 5: Experimental and predicted values of test set molecules based on hypothesis AAHR4 
 
Comp No 
Experimental activity IC50 Predicted activity (μM) 
IC50
 





 1.  33.00  33.86  5.  5.00  4.14 
2.  13.00  12.13  6.  10.7  9.93 
3.  23.00  23.27  7.  6.00  7.64 




Fig. 4: Relation between experimental and predicted P-gp 
inhibitory activity values of test set molecules using model 
AAHR4 
 
In order to gain additional insights about the nature of interactions 
of pyrrolopyrimidines with P-glycoprotein, we visualized and 
analyzed the 3-D QSAR models based on compound 17 using 
hydrogen bond acceptor and hydrophobicity features. 
 
 
Fig. 5: 3-D QSAR model based on compound 17 illustrating 
hydrophobic feature 
 
The 3-D QSAR model based on hydrophobic feature is shown in 
Figure 5. The blue region show hydrophobic substitution at 15 and 
16 position will favour and increase the P-gp inhibitory activity and 
red region at 14 position shows that hydrophobic substitution at 
this position will decrease the activity. The substitutions on the ring 
attached to pyrollopyrimidine also affects the activity as blue 
regions at 3&4 position show that the activity is enhancing on 
substitution with hydrophobic groups and hydrophobic substitution 
at 5th
 
 position will decrease the activity as shown by red regions. 
 
Fig. 6: 3-D QSAR model based on compound 17 illustrating 
electronwithdrawing feature. 
 
In this fig.6 the compound no 17 is having intermediate activity. Blue 
regions show that any electron withdrawing groups at this position 
will increase the activity e.g the iodo group attached to R2 in comp 
no 18 & compounds having 3,4-(F,F)-Ph at R2
CONCLUSION 
 has more activity. Red 
region around nitirile group attached at R indicates that the 
substitutions at these positions by groups having less hydrogen 
bond acceptor property increase the p-gp inhibitory activity. 
Conversion of the nitrile into ketones and the corresponding methyl 
ester gave compounds 4, 6 of test set with increased p-gp activity as 
compared to analogue 17. Transformation of the nitrile into various 
heterocycles such as thiazole, oxadiazole, and pyrimidine 8 of test 
and 7 & 9 of training gave compounds with increasing activity. With 
the more active side chain, 3, 4-difluorophenethylpiperazine the 
simple amide analogue (comp no-22) appeared to be 2-fold more 
potent than the corresponding nitrile analogues at R. 
The studies show the generation of a pharmacophore model AAHR4 
for pyrrolopyrimidines compounds acting as P-gp inhibitors. 
Pharmacophore modeling correlates activities with the spatial 
arrangement of various chemical features. Hypothesis AAHR4 
represents the best pharmacophore model for determining P-gp 
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inhibitory activity. AAHR4 consists of one hydrogen bond acceptor, 
one hydrophobic region and two aromatic ring features. This 
pharmacophore model was able to accurately predict P-gp 
inhibitory activity and the validation results also provide additional 
confidence in the proposed pharmacophore model. AAHR4 can 
provide us a way to rationally design new pyrrolopyrimidines 
compounds as P-gp inhibitors. Results suggested that the proposed 
3-D QSAR model can be useful to identify new promising compounds 
as P-gp inhibitors in large 3-D database of molecules. These 
investigations may be useful for the design of more potent and 
selective p-gp inhibitors for the treatment of a wide variety of 
diseases. 
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